UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Patient-reported impact of symptoms in adrenoleukodystrophy (PRISM-ALD)

Orphanet journal of rare diseases, 2024-03, Vol.19 (1), p.127-127, Article 127

2024

Volltextzugriff (PDF)

Cochleates bridged by drug molecules

International journal of pharmaceutics, 2008-11, Vol.363 (1), p.118-125

2008

Volltextzugriff (PDF)

RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis

Gastroenterology (New York, N.Y. 1943), 2019-02, Vol.156 (3), p.592-603.e10

2019

Volltextzugriff (PDF)

Identification of 8-Nonenal as an Important Contributor to “Plastic” Off-Odor in Polyethylene Packaging

Journal of agricultural and food chemistry, 2005-03, Vol.53 (5), p.1713-1716

2005

Volltextzugriff (PDF)

Sa1111 - Markers of Esophageal Epithelial-Mesenchymal Transition (Emt) are Significantly Reduced in Active Eosinophilic Esophagitis Following 16 Weeks of Treatment with Rpc4046, an Anti-Interleukin-13 Monoclonal Antibody

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-243-S-243

2018

Volltextzugriff (PDF)

Markers of Esophageal Epithelial-Mesenchymal Transition Are Significantly Reduced in Active Eosinophilic Esophagitis Following 16 Weeks of Treatment With RPC4046, an Anti-Interleukin-13 Monoclonal Antibody

Journal of allergy and clinical immunology, 2019-02, Vol.143 (2), p.AB135-AB135

2019

Volltextzugriff (PDF)

Long-Term Efficacy and Safety of RPC4046, an Anti-Interleukin-13 Monoclonal Antibody, in Patients With Eosinophilic Esophagitis: Results From the Open-Label Extension of the HEROES Study

Journal of allergy and clinical immunology, 2019-02, Vol.143 (2), p.AB208-AB208

2019

Volltextzugriff (PDF)

876 - Sustained Long-Term Efficacy and Safety of RPC4046, an Anti-Interleukin-13 Monoclonal Antibody, in Patients with Eosinophilic Esophagitis: Results from the Open-Label Extension of the Heroes Study

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-174-S-175

2018

Volltextzugriff (PDF)

Sa1114 - Efficacy and Safety of Rpc4046, an Anti-Interleukin-13 Monoclonal Antibody, in Patients with Active Eosinophilic Esophagitis: Analysis of the Steroid-Refractory Subgroup from the Heroes Study

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-244-S-244

2018

Volltextzugriff (PDF)

Efficacy of RPC4046, an Anti-Interleukin-13 Monoclonal Antibody, in Patients With Active Eosinophilic Esophagitis: Analysis of the Steroid-Refractory Subgroup From the HEROES Study

Journal of allergy and clinical immunology, 2019-02, Vol.143 (2), p.AB308-AB308

2019

Volltextzugriff (PDF)

A Randomized, Double-Blind, Placebo-Controlled Trial of a Novel Recombinant, Humanized, Anti-Interleukin-13 Monoclonal Antibody (RPC4046) in Patients with Active Eosinophilic Esophagitis: Results of the HEROES Study: 420

The American journal of gastroenterology, 2016-10, Vol.111, p.S186

2016

Volltextzugriff (PDF)